BioSpace News Archive

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported its financial results and business highlights for the second quarter and six months ended June 30, 2020.

- Initiates Phase 1b/2a clinical trial with a proprietary long-acting GLP-1 agonist, in short bowel syndrome; first patients dosed in July and top-line data expected by Q1 2021 - - Amended definition of primary endpoint for Phase 3 trial with larazotide in celiac disease, allowing reduction in participants from 630 to 525 while maintaining statistical powering at 90% -

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, today released its Annual Environmental, Social & Governance Report for 2019.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported second quarter financial results for the period ended June 30, 2020 and provided an update on recent company developments.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces financial results for the three and six months ended June 30, 2020.

Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020. The Company’s revenue for the quarter ended June 30, 2020 was $3.3 million versus $9.3 million for the quarter ended June 30, 2019, a decrease of 64%. Net loss for the quarter ended June 30, 2020 was $2.1 million or ($0.37) per diluted share, versus net income of $0.8 million or $0.14 per diluted share, for the comparable

VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) in patients with platinum-resistant ovarian cancer, and unanimously recommended that the study continue as planned. In this second interim analysis, the DSMC reviewed unblinded Overall Survival (OS)

Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, today announced that it has entered into an Agreement that establishes terms under which Biotricty will enter into a licensing agreement. Biotricity has negotiated to license, with the exclusive right to acquire MD Matrix and its telemedicine platform that includes real-time streaming of medical devices, making it a perfect fit for th

Assure Holdings Corp., a provider of intraoperative neuromonitoring services, is pleased to announce that it has signed an agreement with the largest commercial health insurer in the state of Michigan 1.

PD Theranostics, Inc., provider of AI-driven tools to improve clinical decision-making in serious diseases, and a Laidlaw Venture Partners (“LVP”) portfolio company, today issued the following investor update.